To investigate the safety and effectiveness of medical cannabis (MC) in the real-world clinical practice setting.
Design:
A 4-year prospective noncomparative registry of adult patients who initiated MC for a variety of indications. This paper reports on patients followed for up to 12 months, with interim visits at 3, 6, and 9 months after enrollment.
Setting:
Public or private outpatient clinics certified to authorize MC in the province of Quebec, Canada.
Participants:
Overall, 2991 adult (age ≥18 years) patients (mean age 51 years; 50.2% women) were enrolled between May 2015 and October 2018, with the last follow-up ending in May 2019.
Interventions/Exposures:
Cannabis products (dried, oil, or other) purchased from a Canadian licensed cannabis producer as authorized by physicians.
Main Outcome Measures:
The primary outcomes were self-reported pain severity, interference and relief (Brief Pain Inventory [BPI]), symptoms using the Revised Edmonton Symptom Assessment System (ESAS-r) and health-related quality of life dimensions (EQ-5D-5L) at baseline and each follow-up visit. The secondary outcomes were self-reported adverse events (AEs) and characteristics of cannabis treatment.
Results:
All patient-reported outcomes (BPI, ESAS-r, and EQ-5D-5L) showed a statistically significant improvement at 3 months (all p<0.01), which was maintained or further improved (for pain interference, tiredness, and well-being) over the remainder of the 12-month follow-up. Results also revealed clinically significant improvements in pain interference and tiredness, anxiety, and well-being from baseline. There were 79 AE reports (77 patients), 16 met the regulatory definition of seriousness, in which only 8 AEs were certainly or probably related to MC.
Conclusions:
MC directed by physicians appears to be safe and effective within 3 months of initiation for a variety of medical indications.
Get full access to this article
View all access options for this article.
References
1.
Government of Canada. Marijuana Medical Access Regulations (SOR/2001-227). Internet: Government of Canada, Ottawa; 2014.
2.
Government of Canada. Marijuana for Medical Purposes Regulations (SOR/2013-119). Internet: Government of Canada, Ottawa; 2014.
3.
UN commission reclassifies cannabis, yet still considered harmful UN News: United Nations; 2020. Available from: https://news.un.org/en/story/2020/12/1079132 [Last accessed: April 14, 2022].
4.
RønneST, RosenbækF, PedersenLB, et al.Physicians' experiences, attitudes, and beliefs towards medical cannabis: A systematic literature review. BMC Fam Pract, 2021; 22(1):212; doi: 10.1186/s12875-021-01559-w.
5.
KarangesEA, SuraevA, EliasN, et al.Knowledge and attitudes of Australian general practitioners towards medicinal cannabis: A cross-sectional survey. BMJ Open, 2018; 8(7):e022101; doi: 10.1136/bmjopen-2018-022101.
6.
CrowleyD, CollinsC, DelargyI, et al.Irish general practitioner attitudes toward decriminalisation and medical use of cannabis: Results from a national survey. Harm Reduct J, 2017; 14(1):4; doi: 10.1186/s12954-016-0129-7.
7.
ZiemianskiD, CaplerR, TekanoffR, et al.Cannabis in medicine: A national educational needs assessment among Canadian physicians. BMC Med Educ, 2015; 15(1):52; doi: 10.1186/s12909-015-0335-0.
8.
BanerjeeR, ErridgeS, SalazarO, et al.Real world evidence in medical cannabis research. Ther Innov Regul Sci, 2022; 56(1):8–14; doi: 10.1007/s43441-021-00346-0.
9.
WareMA, AdamsH, GuyGW. The medicinal use of cannabis in the UK: Results of a nationwide survey. Int J Clin Pract, 2005; 59(3):291–295; doi: 10.1111/j.1742-1241.2004.00271.x.
10.
SextonM, CuttlerC, FinnellJS, et al.A cross-sectional survey of medical cannabis users: Patterns of use and perceived efficacy. Cannabis Cannabinoid Res, 2016; 1(1):131–138; doi: 10.1089/can.2016.0007.
11.
LucasP, WalshZ. Medical cannabis access, use, and substitution for prescription opioids and other substances: A survey of authorized medical cannabis patients. Int J Drug Policy, 2017; 42:30–35; doi: 10.1016/j.drugpo.2017.01.011.
12.
LintzerisN, MillsL, SuraevA, et al.Medical cannabis use in the Australian community following introduction of legal access: The 2018–2019 Online Cross-Sectional Cannabis as Medicine Survey (CAMS-18). Harm Reduct J, 2020; 17(1):37; doi: 10.1186/s12954-020-00377-0.
13.
GrahamM, BirdS, HowardZ, et al.NSW Cannabis Medicines Advisory Service preliminary survey results: Enquirer perceptions and patient outcomes. Internal Med J, 2022; 52(2):228–237; doi: 10.1111/imj.15635.
14.
BachhuberMA, SalonerB, CunninghamCO, et al.Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999–2010. JAMA Internal Med, 2014; 174(10):1668–1673; doi: 10.1001/jamainternmed.2014.4005.
15.
PiperBJ, DesrosiersCE, FisherHC, et al.A new tool to tackle the opioid epidemic: Description, utility, and results from the maine diversion alert program. Pharmacotherapy, 2017; 37(7):791–798; doi: 10.1002/phar.1952.
16.
Moreno-SanzG, MadiedoA, HernandezP, et al.Sex-dependent prescription patterns and clinical outcomes associated with the use of two oral cannabis formulations in the multimodal management of chronic pain patients in Colombia. Front Pain Res (Lausanne, Switzerland), 2022; 3:854795; doi: 10.3389/fpain.2022.854795.
17.
RapinL, GamaounR, El HageC, et al.Cannabidiol use and effectiveness: Real-world evidence from a Canadian medical cannabis clinic. J Cannabis Res, 2021; 3(1):19; doi: 10.1186/s42238-021-00078-w.
18.
GulbransenG, XuW, ArrollB. Cannabidiol prescription in clinical practice: An audit on the first 400 patients in New Zealand. BJGP Open, 2020; 4(1); doi: 10.3399/bjgpopen20X101010.
19.
Bonn-MillerMO, BodenMT, BucossiMM, et al.Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. Am J Drug Alcohol Abuse, 2014; 40(1):23–30; doi: 10.3109/00952990.2013.821477.
20.
HabibG, AvisarI. The consumption of cannabis by fibromyalgia patients in Israel. Pain Res Treat, 2018; 2018:7829427; doi: 10.1155/2018/7829427.
21.
UeberallMA, EssnerU, Mueller-SchwefeGH. Effectiveness and tolerability of THC:CBD oromucosal spray as add-on measure in patients with severe chronic pain: Analysis of 12-week open-label real-world data provided by the German Pain e-Registry. J Pain Res, 2019; 12:1577–1604; doi: 10.2147/jpr.S192174.
22.
MahabirVK, MerchantJJ, SmithC, et al.Medical cannabis use in the United States: A retrospective database study. J Cannabis Res, 2020; 2(1):32; doi: 10.1186/s42238-020-00038-w.
23.
Quebec Medical College. Guidelines Concerning the Prescription of Dried Cannabis for Medical Purposes. Quebec Medical College: Quebec; 2014.
24.
von ElmE, AltmanDG, EggerM, et al.Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. BMJ (Clinical research ed), 2007; 335(7624):806–808; doi: 10.1136/bmj.39335.541782.AD.
College of Family Physicians of Canada. Authorizing Dried Cannabis for Chronic Pain or Anxiety: Preliminary Guidance from the College of Family Physicians of Canada. College of Family Physicians of Canada: Mississauga, ON; 2014.
27.
CleelandCS.Brief Pain Inventory. In: Handbook of Pain Assessment. (Turk DC, Melzack R, eds.). Guilford Press: New York; 1991; pp. 378–382.
28.
BrueraE, KuehnN, MillerMJ, et al.The Edmonton Symptom Assessment System (ESAS): A simple method for the assessment of palliative care patients. J Palliat Care, 1991; 7(2):6–9; doi: 10.1177/082585979100700202.
XieF, PullenayegumE, GaebelK, et al.A Time Trade-off-derived Value Set of the EQ-5D-5L for Canada. Med Care, 2016; 54(1):98–105; doi: 10.1097/mlr.0000000000000447.
31.
CastillonG, SalvoF, MorideY. The social impact of suspected adverse drug reactions: An analysis of the Canada Vigilance Spontaneous Reporting Database. Drug Saf, 2019; 42(1):27–34; doi: 10.1007/s40264-018-0713-8.
32.
BaselyousY, De CocinisM, IbrahimM, et al.Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA. Expert Opin Drug Saf, 2019; 18(3):153–161; doi: 10.1080/14740338.2019.1589447.
33.
AkinolaS, da SilveiraCG, CorbinS, et al.Using data from the Canadian post-marketing spontaneous pharmacovigilance system for drug safety research: A feasibility study. Pharm Med, 2020; 34(4):263–269; doi: 10.1007/s40290-020-00345-w.
34.
HazekampA, HeerdinkER. The prevalence and incidence of medicinal cannabis on prescription in The Netherlands. Eur J Clin Pharmacol, 2013; 69(8):1575–1580; doi: 10.1007/s00228-013-1503-y.
35.
BeaulieuP, BoulangerA, DesrochesJ, et al.Medical cannabis: Considerations for the anesthesiologist and pain physician. Can J Anaesth, 2016; 63(5):608–624; doi: 10.1007/s12630-016-0598-x.
36.
ZolotovY, EshetL, MoragO. Preliminary assessment of medical cannabis consumption by cancer survivors. Complement Ther Med, 2021; 56:102592; doi: 10.1016/j.ctim.2020.102592.
37.
NaftaliT, Bar-Lev SchleiderL, Sklerovsky BenjaminovF, et al.Medical cannabis for inflammatory bowel disease: Real-life experience of mode of consumption and assessment of side-effects. Eur J Gastroenterol Hepatol, 2019; 31(11):1376–1381; doi: 10.1097/meg.0000000000001565.
38.
WareMA, WangT, ShapiroS, et al.Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain, 2015; 16(12):1233–1242; doi: 10.1016/j.jpain.2015.07.014.
39.
BhaskarA, BellA, BoivinM, et al.Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: Results of a modified Delphi process. J Cannabis Res, 2021; 3(1):22; doi: 10.1186/s42238-021-00073-1.
40.
MacCallumCA, LoLA, BoivinM. “Is medical cannabis safe for my patients?” A practical review of cannabis safety considerations. Eur J Internal Med, 2021; 89:10–18; doi: 10.1016/j.ejim.2021.05.002.
41.
MacCallumCA, RussoEB. Practical considerations in medical cannabis administration and dosing. Eur J Internal Med, 2018; 49:12–19; doi: 10.1016/j.ejim.2018.01.004.
42.
DavisMP, CaseAA, CyrC.Do we have structure, process and outcomes to support cannabis as supportive therapy in cancer?. Am J Hosp Palliat Care, 2022:10499091221101561; doi: 10.1177/10499091221101561.
43.
WebbCW, WebbSM. Therapeutic benefits of cannabis: A patient survey. Hawai'i J Med Public Health, 2014; 73(4):109–111.
44.
WalshZ, CallawayR, Belle-IsleL, et al.Cannabis for therapeutic purposes: Patient characteristics, access, and reasons for use. Int J Drug Policy, 2013; 24(6):511–516; doi: 10.1016/j.drugpo.2013.08.010.
45.
KalabaM, MacNairL, PetersEN, et al.Authorization patterns, safety, and effectiveness of medical cannabis in Quebec. Cannabis Cannabinoid Res, 2021; 6(6):564–572; doi: 10.1089/can.2020.0140.
46.
SafakishR, KoG, SalimpourV, et al.Medical cannabis for the management of pain and quality of life in chronic pain patients: A prospective observational study. Pain Med (Malden, Mass), 2020; 21(11):3073–3086; doi: 10.1093/pm/pnaa163.
47.
SagyI, Bar-Lev SchleiderL, Abu-ShakraM, et al.Safety and efficacy of medical cannabis in fibromyalgia. J Clin Med, 2019; 8(6); doi: 10.3390/jcm8060807.
48.
CrescioliG, LombardiN, BettiolA, et al.Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database. Br J Clin Pharmacol, 2020; 86(1):106–120; doi: 10.1111/bcp.14140.
49.
MengH, PageMG, AjrawatP, et al.Patient-reported outcomes in those consuming medical cannabis: A prospective longitudinal observational study in chronic pain patients. Can J Anaesth, 2021; 68(5):633–644; doi: 10.1007/s12630-020-01903-1.
50.
AviramJ, PudD, GershoniT, et al.Medical cannabis treatment for chronic pain: Outcomes and prediction of response. Eur J Pain (London, England), 2021; 25(2):359–374; doi: 10.1002/ejp.1675.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
